Skip to content

EB Pharma Developments

Active Private limited companyfounded 2022active for 4 yearsAlkerstraat 28, 3570 AlkenKBO/BCE: BE 0780.755.671

Lifetime

4 annual accounts with figures on one time axis
peak of €20,964 in 2022
-€1,127▼ €4,876
lowest -€4,644 in 2023
-€1,347▼ €4,913
peak of €17,722 in 2022
€5,298▼ 68.2%
€11,654▲ 382%
Board1 name since 2022
1 director
Documentsfilings and deeds
25-03-2026128 days before the deadline
2025abbreviated format
Gross margin from €3,749 to -€1,127Loss of €1,347Dividend €10,000Equity from €16,645 to €5,298Debts from €2,420 to €11,654

Key points

from the 2025 annual accounts

Equity

€5,298 ▼ 68.2%
16,6452024-1,347Loss-10,000Dividend5,2982025

EB Pharma Developments paid out €10,000 in dividends in a year with a loss of €1,347.

Liquidity

1.45 was 7.88 in 2024

Short-term debts rose from €2,420 to €11,654.

Position in the sector

€5,298

Less equity than 84% of companies in other professional activities. The sector median is €147,244, over 734 companies.

Turnover not published in the abbreviated or micro format

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,152 companies had the same profile as EB Pharma Developments has now. Each dot stands for 6 companies, two years later.

91.6%
were still trading
6.1%
stopped another way
2.2%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a small loss
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,152 companies, not a prediction for EB Pharma Developments. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 19-01-2022
  • 100 sharesdeed of 25-01-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0780755671
Incorporation Founding capital of €1,500, 100 shares · Founded by (sole founder) · appointed as director · published on 25-01-2022 · Gazette deed
First establishment Alkerstraat 28, Alken
All 9 events

Comparable companies

same main activity, similar in size and age
Company
EB Pharma Developments Alken €16,951 -€1,127 31.3% -
Panda International Belgium Brussels €17,295 -€17,526 -55.4% -
DEMATTEST Wellen €22,993 -€11,014 -82.1% -
VEC Lo-Reninge €15,157 -€3,990 51.5% -
P-QUID Floreffe €12,492 -€742 92.3% -
Fidan B Antwerp €14,576 -€1,072 94.4% -
NANCY MAHAUX Andenne €23,795 -€9,078 93.3% -

These companies have the same main activity as EB Pharma Developments: other professional, scientific and technical activities (NACE 74999). They are comparable in size and age: total assets between €12,500 and €23,800, founded between 2021 and 2023.

Official details

Source: KBO
Status
Active since 21-01-2022Normal situation
Activity
Other professional, scientific and technical activitiesNACE 74999and 2 others
Establishment unit
2.327.009.2143570 Alken, since 21-01-2022
Financial year end
31 December
Peppol
Reachable since 23-04-2026
Company details

Annual accounts 2025

€16,951▼ 11.1%
Filing
Filed on 25-03-2026, 128 days before the end of the filing period
Financials

Insights on EB Pharma Developments

EB Pharma Developments files the abbreviated format. That format states no turnover. The gross margin fell from €20,964 in 2022 to -€1,127 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about EB Pharma Developments

What is the company number of EB Pharma Developments?
The company number of EB Pharma Developments is 0780.755.671. The VAT number is the same number with BE in front: BE 0780.755.671.
Where is EB Pharma Developments based?
The registered office is at Alkerstraat 28, 3570 Alken.Company details
What does EB Pharma Developments do?
According to the KBO register, the main activity is other professional, scientific and technical activities (NACE 74999).
What is the legal form of EB Pharma Developments?
EB Pharma Developments is a private limited company (BV).
When was EB Pharma Developments founded?
EB Pharma Developments was founded on 21-01-2022.
Is EB Pharma Developments still active?
Yes, EB Pharma Developments is an active enterprise in the KBO register.
What is the turnover of EB Pharma Developments?
The annual accounts for financial year 2025 state no turnover. The abbreviated or micro format does not require it.Financials
Is EB Pharma Developments profitable?
In financial year 2025, EB Pharma Developments made a loss of €1,347.
Where can I find the annual accounts of EB Pharma Developments?
EB Pharma Developments filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of EB Pharma Developments due?
EB Pharma Developments must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.